Champions Oncology, Inc..
CSBR.US | Research and experimental development on natural sciences and engineering
Champions Oncology, Inc. is a global oncology solutions company that develops and commercializes advanced technology solutions and services to personalize the development and use of oncology drugs. The company's offerings include: (1) Champions TumorGraft® (CTG) platform, which involves the developm...Show More
Better Health for All
40
Champions Oncology, Inc. is a global oncology solutions company focused on developing and commercializing technology solutions and services for oncology drug development. Its entire business is devoted to health improvement, including platforms and biopharma services that support cancer treatment development. The company participated in pre-clinical studies to identify a novel therapy for childhood cancer, demonstrating a focus on significant health challenges.
1
The company's R&D expenditure was $9.5 million in 2024 against a revenue of $50.2 million, representing 18.9% of revenue.
2
In 2023, R&D expenditure was $11.5 million against a revenue of $53.9 million, representing 21.3% of revenue.
3
There is no evidence of the company generating revenue from products with negative health outcomes.
Fair Money & Economic Opportunity
0
Champions Oncology, Inc. is an oncology solutions company that provides services to pharmaceutical and biotechnology companies, and academic research institutions.
1
Its core business does not involve lending, insuring, moving, or storing money for consumers or underserved populations.
2
Therefore, all KPIs related to financial products, lending practices, customer financial data, and financial inclusion initiatives are not applicable to its business model.
Fair Pay & Worker Respect
-50
Employee reviews indicate a low level of worker engagement, with only 39% of employees recommending working at the company and 42% approving of the CEO.
1
The overall employee rating is 2.7 out of 5 stars, which is significantly below the Pharmaceutical & Biotechnology industry average of 3.5 stars.
2
The company also experiences an extremely high voluntary employee turnover rate, with frequent manager and coworker changes repeatedly cited as a significant concern in employee reviews.
3
Fair Trade & Ethical Sourcing
0
No evidence was found in the provided articles regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical sourcing clauses in supplier contracts, the share of spend on high-risk materials, or procurement budget directed to diverse suppliers.
1
Therefore, no KPIs can be scored for Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
The provided articles do not contain specific, concrete data points for any of the KPIs related to Honest & Fair Business, such as regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification of ethical claims.
1
The articles explicitly state that no data is available or the information is not mentioned for all relevant KPIs.
Kind to Animals
-40
Champions Oncology, Inc. received a Case B OLAW Noncompliance Correspondence in 2024, indicating inconsistent enforcement or reporting regarding its animal testing policies.
1
The company's core business involves the use of immunocompromised mice for tumor implantation, drug administration, surgery, and euthanasia procedures, as evidenced by job descriptions for Laboratory Research Associates.
2
No War, No Weapons
0
The provided articles, including the company's Form 10-K for the fiscal year ended April 30, 2024, explicitly state that no data relevant to arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investment, conflict divestment policy, board oversight of defense, export certifications, lobbying, humanitarian compliance, human rights due diligence, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use screening, surveillance transparency, ethical red lines, zero exposure to controversial weapons, war risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace tech investment, or conflict zone procurement was found.
1
The company's core business is focused on oncology research and services.
2
Therefore, no KPIs can be scored based on the evidence provided.
Planet-Friendly Business
-10
The company's total Scope 1, 2, and 3 greenhouse gas emissions for 2023 were 856.8 tCO₂e.
1
In 2023, direct manufacturing emissions were reduced by 35%, indirect energy by 28%, and transportation by 22%.
2
Champions Oncology has Scope 1 and 2 emissions reduction targets of 42% by 2030 (baseline 2020) that are validated through a streamlined process for SMEs, aligning with 1.5°C reduction targets.
3
The company's waste diversion rate is 68%.
4
Respect for Cultures & Communities
0
No evidence available to assess Champions Oncology, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Champions Oncology, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
-20
Champions Oncology has set a company-wide target to reduce waste to landfill by 30% by 2028.
1
No other specific, quantitative data points related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, supplier waste requirements, or customer waste education were provided in the articles.